Spatial Transcriptomics Platforms Compared: Choosing the Right Technology for Your Study

Spatial transcriptomics (ST) has moved from a specialized technique to a core tool in life science research, enabling researchers to measure gene expression while preserving the native tissue architecture. This article compares the major commercial and open ST platforms, including 10x Visium, Xenium, Slide-seq, MERFISH, CosMx, and Stereo-seq, across resolution, throughput, sensitivity, sample compatibility, and cost. The practical outcome is a decision framework that helps researchers match platform capabilities to their specific experimental questions, sample types, and budgets, supported by recent head-to-head benchmarking studies.

Understanding the Two Main Technology Families

Spatial transcriptomics platforms fall into two broad categories based on how they capture and read gene expression signals. Sequencing-based methods use spatially barcoded capture probes on slides or beads, followed by next-generation sequencing to read out the transcripts. Imaging-based methods use fluorescence microscopy to directly visualize and quantify RNA molecules in situ, either through targeted probe hybridization or in situ sequencing.

The distinction matters for experimental design because each family has different strengths and constraints. Sequencing-based methods typically offer whole-transcriptome coverage, meaning they can detect thousands of genes without prior selection. Imaging-based methods generally provide single-cell or subcellular resolution but require a predefined gene panel, which limits discovery to the genes you choose to include.

A 2024 systematic comparison of 11 sequencing-based spatial transcriptomics methods established a reference tissue collection with well-defined histological architectures to benchmark platform performance. The study highlighted molecular diffusion as a variable parameter across methods and tissues, significantly affecting effective resolutions. The authors also observed that spatial transcriptomic data demonstrate unique attributes beyond adding a spatial axis to single-cell data, including an enhanced ability to capture patterned rare cell states along with specific markers, albeit influenced by multiple factors including sequencing depth and resolution. This work assists biologists in platform selection and establishes a framework for future benchmarking efforts that can serve as a gold standard for computational tool development.

At a Glance: Platform Comparison Decision Table

The table below summarizes key characteristics of major spatial transcriptomics platforms based on published benchmarking studies. Scores reflect relative performance within the context of the cited comparisons, not absolute values.

Key Platform Categories and Their Tradeoffs

Sequencing-Based Platforms: Whole-Transcriptome Discovery

Sequencing-based spatial transcriptomics platforms use spatially barcoded capture surfaces to bind mRNA from tissue sections. After library preparation and sequencing, the spatial barcode reveals where each transcript originated. The main advantage is whole-transcriptome coverage, which allows unbiased discovery of differentially expressed genes without prior knowledge of which genes matter.

10x Visium is the most widely used sequencing-based platform. It uses capture spots approximately 55 micrometers in diameter, each containing spatial barcodes. Because each spot captures RNA from multiple cells, downstream analysis often requires deconvolution to estimate cell-type composition within each spot. A 2022 comparison of cell-type composition inference methods for spatial transcriptomics data concluded that RCTD and stereoscope achieve more robust and accurate inferences when estimating cell-type proportions from spot-level data. This finding matters for researchers planning to use Visium data for cell-type analysis, as the choice of deconvolution tool can substantially affect results.

Visium HD represents an evolution toward higher resolution while retaining whole-transcriptome coverage. The platform uses smaller capture tiles, enabling analysis at a finer scale than standard Visium. A 2026 technical comparison across five commercial ST platforms using matched FFPE human tumor sections from six cancer types included Visium v1, Visium v2/CytAssist, and Visium HD. The study evaluated transcript and UMI detection, gene-histology concordance, cell type recovery, and integration with a targeted protein panel. The authors quantified the impact of sampling strategies and area coverage on cell type estimation, revealing trade-offs in spatial resolution versus tissue context.

Slide-seq uses DNA-barcoded beads randomly packed on a slide, achieving bead-level resolution around 10 micrometers. This provides higher spatial resolution than Visium while maintaining whole-transcriptome coverage. However, the random bead placement requires computational mapping to reconstruct spatial positions, and the platform typically requires fresh frozen tissue.

Imaging-Based Platforms: Single-Cell Resolution with Targeted Panels

Imaging-based spatial transcriptomics platforms use fluorescence in situ hybridization approaches to detect and quantify RNA molecules directly in tissue sections. These platforms achieve single-cell or subcellular resolution but require a predefined gene panel.

A 2025 study in Nature Communications compared imaging-based single-cell resolution ST platforms using serial 5 micrometer sections of FFPE surgically resected lung adenocarcinoma and pleural mesothelioma samples in tissue microarrays. The comparison included CosMx, MERFISH, and Xenium (uni/multi-modal) platforms, referenced against bulk RNA sequencing, multiplex immunofluorescence, GeoMx, and hematoxylin and eosin staining data. The study performed objective assessment of automatic cell segmentation and phenotyping, plus manual phenotyping evaluation to assess pathologically meaningful comparisons. The authors showed intricate differences between platforms and revealed the importance of parameters such as probe design in determining data quality. They suggested reliable workflows for accurate spatial profiling and molecular discovery.

A preprint version of this work, published in Research Square in 2025, added that tissue age and probe design are important parameters affecting data quality. A bioRxiv preprint from 2024 reported similar findings, emphasizing that tissue age and probe design influence data quality in imaging-based platforms.

The Xenium platform from 10x Genomics offers targeted gene panels ranging from approximately 100 to 5,000 genes. A 2026 study in eLife investigated off-target probe binding affecting Xenium gene panels. The authors developed a software tool called Off-target Probe Tracker (OPT) to identify putative off-target binding by aligning probe target sequences and assessing whether mapped loci corresponded to the intended target gene across multiple reference annotations. Applying OPT to a Xenium human breast gene panel, they identified at least 14 of 313 genes potentially impacted by off-target binding to protein-coding genes. Using a Xenium breast cancer dataset generated with this panel, they compared results to orthogonal spatial and single-cell transcriptomic profiles from Visium CytAssist and 3-prime single-cell RNA-seq derived from the same tumor block. Their findings indicated that for some genes, the expression patterns detected by Xenium reflected the aggregate expression of the target and predicted off-target genes instead of the target gene alone. This work enhances biological interpretability and improves reproducibility in spatial transcriptomics research.

The CosMx platform from NanoString offers high-plex targeted panels with single-cell resolution. The 2025 Nature Communications study included CosMx in its comparison and found that probe design and tissue age affect data quality. The platform supports protein co-detection, enabling spatial multi-omics analysis.

MERFISH (multiplexed error-robust fluorescence in situ hybridization) uses combinatorial barcoding to detect hundreds to thousands of genes simultaneously. The 2025 Nature Communications study included MERFISH in its comparison of imaging-based platforms. MERFISH requires careful panel design and tissue processing optimization.

Emerging and Alternative Platforms

Stereo-seq is a sequencing-based platform that uses patterned capture arrays to achieve high spatial resolution with whole-transcriptome coverage. A 2025 review in the International Journal of Molecular Sciences discussed Stereo-seq V2 among technologies enhancing RNA capture efficiency, noting progress in addressing challenges related to RNA diffusion, probe density, and tissue processing.

Decoder-seq and MAGIC-seq are additional emerging sequencing-based platforms discussed in the same review. These technologies use nanomaterial-enhanced capture and microfluidic chip optimization to improve RNA capture efficiency.

A 2023 study in BMC Genomics compared the Illumina NextSeq 2000 and GeneMind Genolab M sequencing platforms for 10x Genomics Visium spatial transcriptomics. The comparison demonstrated that the GeneMind Genolab M sequencing platform produces highly consistent results with the Illumina NextSeq 2000. Both platforms showed similar performance in sequencing quality and detection of UMI, spatial barcode, and probe sequence. Raw read mapping and read counting produced highly comparable results, confirmed by quality control metrics and strong correlation between expression profiles in the same tissue spots. Downstream analysis including dimension reduction and clustering demonstrated similar results, and differential gene expression analysis predominantly detected the same genes for both platforms. This finding is relevant for researchers considering lower-cost sequencing alternatives.

Resolution, Throughput, and Sensitivity: What the Benchmarks Show

Effective Resolution Versus Nominal Resolution

Nominal resolution describes the physical capture unit of a platform, such as spot size or bead diameter. Effective resolution describes the actual spatial precision achieved after accounting for molecular diffusion and tissue processing effects. The 2024 Nature Methods study of 11 sequencing-based methods highlighted molecular diffusion as a variable parameter across different methods and tissues, significantly affecting effective resolutions. This means that a platform with nominally high resolution may not achieve that resolution in practice if diffusion spreads transcripts beyond their originating cells.

For imaging-based platforms, the 2025 Nature Communications study found that automatic cell segmentation and phenotyping performance varied across platforms. Manual phenotyping evaluation revealed pathologically meaningful differences between platforms, suggesting that automated segmentation may not always align with pathologist assessment.

Throughput Considerations

Throughput in spatial transcriptomics has two dimensions: the number of genes detected per experiment and the tissue area covered. Sequencing-based platforms generally provide whole-transcriptome coverage, detecting thousands of genes simultaneously. Imaging-based platforms are limited to the genes in the selected panel, though panels have expanded to 5,000 genes or more.

The 2026 Genome Biology study provided the first same-sample comparison of Xenium Multi-Tissue (377 genes) and Xenium Prime (5,000 genes), highlighting key differences in transcript recovery and spatial signal despite shared chemistry and imaging infrastructure. This finding is directly relevant for researchers choosing between Xenium panel sizes, as the larger panel may not simply provide more genes without tradeoffs in detection efficiency.

Sensitivity and RNA Capture Efficiency

RNA capture efficiency varies substantially across platforms. A 2025 review in the International Journal of Molecular Sciences systematically reviewed innovative technologies and strategies that have enhanced spatial transcriptome RNA capture efficiency, including nanomaterial-enhanced capture, optimization of microfluidic chips, advancements in molecular biology techniques, and computationally assisted prediction methods. The review emphasized optimization approaches for FFPE clinical samples and computational prediction methodologies that integrate artificial intelligence.

The 2026 Genome Biology study evaluated transcript and UMI detection across five commercial ST platforms using matched FFPE human tumor sections. The authors found that sampling strategies and area coverage affect cell type estimation, revealing trade-offs in spatial resolution versus tissue context.

Sample Type Compatibility and Tissue Processing

FFPE Samples

Formalin-fixed paraffin-embedded (FFPE) samples represent the most common tissue format in clinical and pathology archives. The 2026 Genome Biology study systematically benchmarked five commercial ST platforms using matched FFPE human tumor sections from six cancer types, including both sequencing-based and imaging-based platforms profiled on the same samples. This enabled direct technical comparisons across spatial capture modalities.

The 2025 Nature Communications study used FFPE surgically resected lung adenocarcinoma and pleural mesothelioma samples in tissue microarrays to compare CosMx, MERFISH, and Xenium platforms. The study found that tissue age affects data quality, meaning that older FFPE blocks may yield poorer results regardless of platform choice.

Fresh Frozen Samples

Fresh frozen tissue is generally preferred for sequencing-based platforms because RNA quality is higher. Slide-seq requires fresh frozen tissue. Visium supports both fresh frozen and FFPE samples, with dedicated protocols for each.

Compatibility With Protein Detection

Some platforms support simultaneous detection of RNA and protein. The 2026 Genome Biology study integrated Visium targeted protein data with matched RNA profiles, uncovering widespread RNA-protein decoupling and spatial heterogeneity in concordance. This finding has implications for researchers planning multi-omics studies, as RNA and protein levels may not correlate spatially.

Practical Workflow for Platform Selection

Step 1: Define Your Research Question

Start by clarifying what biological question you need to answer. If you need to discover novel genes or pathways without prior hypotheses, a whole-transcriptome sequencing-based platform such as Visium or Slide-seq is appropriate. If you have a defined gene panel and need single-cell resolution, an imaging-based platform such as Xenium, CosMx, or MERFISH is more suitable.

Step 2: Assess Your Sample Type and Quality

Determine whether your samples are FFPE or fresh frozen, and assess tissue age and RNA quality. Older FFPE blocks may produce poorer data quality on imaging-based platforms, as the 2025 Nature Communications study demonstrated. If your samples are limited or precious, consider which platform requires the least tissue and provides the most reliable data.

Step 3: Evaluate Resolution Requirements

Consider whether spot-level resolution is sufficient for your question or whether you need single-cell resolution. Spot-level platforms capture multiple cells per spot, requiring computational deconvolution to estimate cell-type composition. The 2022 Briefings in Bioinformatics study found that RCTD and stereoscope achieve more robust and accurate inferences for cell-type decomposition. If your analysis depends on accurate cell-type identification, factor in the need for deconvolution and choose a platform and analysis pipeline accordingly.

Step 4: Consider Panel Design for Imaging Platforms

If you choose an imaging-based platform, panel design is a critical decision. The 2025 Nature Communications study revealed the importance of probe design in determining data quality. The 2026 eLife study documented off-target probe binding in Xenium panels, identifying at least 14 of 313 genes in a breast cancer panel potentially impacted by off-target binding. Use tools such as Off-target Probe Tracker to screen custom panels for potential off-target effects before committing to an experiment.

Step 5: Budget for Sequencing and Analysis

Sequencing-based platforms require downstream sequencing, which adds cost and time. The 2023 BMC Genomics study demonstrated that the GeneMind Genolab M platform produces results highly consistent with the Illumina NextSeq 2000 for Visium spatial transcriptomics, offering a potential lower-cost sequencing alternative. Factor in sequencing costs when comparing platform options.

Step 6: Plan for Data Analysis and Integration

Spatial transcriptomics data analysis requires specialized computational tools. The 2026 benchmarking study in Genome Biology evaluated nine computational cell-cell interaction inference methods on Visium, Stereo-seq, and Xenium datasets, demonstrating substantial variability in tool performance across spatial resolutions, tissue contexts, and platforms. The 2026 Nature Communications study introduced FineST, a deep contrastive learning model that integrates histology and spatial transcriptomics for nuclei-resolved ligand-receptor analysis. Consider which analysis tools you will need and whether your team has the computational expertise to run them.

Records and Measurements for Platform Evaluation

When comparing platforms or evaluating data quality, maintain consistent records across the following measurements:

Transcript and UMI Detection

Record the number of transcripts and unique molecular identifiers (UMIs) detected per spot, bead, or cell. The 2026 Genome Biology study evaluated these metrics across five platforms and found substantial variation. Higher detection does not always mean better data, as it may reflect technical artifacts or off-target binding.

Gene-Histology Concordance

Assess whether detected gene expression patterns align with known histological structures. The 2026 Genome Biology study evaluated gene-histology concordance across platforms. Poor concordance may indicate technical issues such as RNA diffusion or probe misbinding.

Cell Type Recovery

Evaluate whether the platform and analysis pipeline recover expected cell types in your tissue. The 2026 Genome Biology study assessed cell type recovery across platforms and found that sampling strategies and area coverage affect cell type estimation.

Segmentation Quality

For imaging-based platforms, assess automatic cell segmentation quality. The 2025 Nature Communications study performed objective assessment of automatic cell segmentation and phenotyping, plus manual phenotyping evaluation. Discrepancies between automatic and manual assessment indicate segmentation limitations.

Reproducibility Metrics

The 2026 Nature Biotechnology study addressed standardized metrics for assessment and reproducibility of imaging-based spatial transcriptomics datasets. Use standardized metrics where available to enable comparison across experiments and laboratories.

Common Failure Patterns and How to Avoid Them

RNA Diffusion and Resolution Loss

Molecular diffusion can reduce effective resolution in sequencing-based platforms. The 2024 Nature Methods study identified diffusion as a variable parameter across methods and tissues. To mitigate this, optimize tissue permeabilization times and follow platform-specific protocols carefully.

Off-Target Probe Binding

Imaging-based platforms using targeted panels are susceptible to off-target probe binding. The 2026 eLife study documented this issue in Xenium panels and developed the Off-target Probe Tracker tool to identify potential problems. Screen custom panels before experiments and validate suspicious genes with orthogonal methods such as Visium or single-cell RNA-seq.

Poor FFPE Sample Quality

Tissue age and fixation quality affect data quality in imaging-based platforms. The 2025 Nature Communications study and its preprint versions found that tissue age is an important parameter. For old or poorly preserved FFPE blocks, consider whether sequencing-based platforms may be more tolerant or whether RNA quality assessment is needed before proceeding.

Inadequate Sequencing Depth

Sequencing-based platforms require sufficient sequencing depth for reliable detection. The 2024 Nature Methods study noted that sequencing depth influences the ability to capture patterned rare cell states. Plan sequencing depth based on tissue area and expected transcript density.

Deconvolution Errors

Spot-level platforms require computational deconvolution to estimate cell-type composition. The 2022 Briefings in Bioinformatics study found that deconvolution method choice substantially affects results, with RCTD and stereoscope performing more robustly. Use validated deconvolution tools and validate results with orthogonal methods where possible.

Limitations and Interpretation Caveats

Panel Bias in Imaging Platforms

Imaging-based platforms only detect genes included in the panel. This creates a selection bias that limits discovery. The 2026 Genome Biology study compared Xenium Multi-Tissue (377 genes) and Xenium Prime (5,000 genes), finding key differences in transcript recovery and spatial signal. Larger panels may reduce sensitivity for individual genes.

RNA-Protein Decoupling

The 2026 Genome Biology study integrated Visium targeted protein data with matched RNA profiles, uncovering widespread RNA-protein decoupling and spatial heterogeneity in concordance. This means that RNA expression patterns may not predict protein abundance at the same spatial location. Interpret RNA-based spatial data with this limitation in mind.

Computational Complexity

Spatial transcriptomics data analysis is computationally intensive and requires specialized expertise. The 2026 Biotechnology Advances review noted that the field faces challenges including technical complexity, difficulties in data analysis, and lack of standardization. Budget time and resources for analysis, beyond data generation.

Lack of Standardization

The 2026 Biotechnology Advances review highlighted the lack of standardization in spatial transcriptomics. Different platforms, analysis pipelines, and quality metrics make cross-study comparison difficult. The 2026 Nature Biotechnology study proposed standardized metrics for imaging-based datasets, which may improve comparability over time.

Safety and Regulatory Context

Data Sharing and Genomic Data Policies

Spatial transcriptomics generates large-scale genomic data that may be subject to data sharing policies. The NIH Genomic Data Sharing Policy at https://sharing.nih.gov/genomic-data-sharing-policy describes expectations for sharing genomic data generated with NIH funding. Researchers should review applicable policies before generating data and plan for data deposition in appropriate repositories.

Data Repositories

The NCBI Data Resources at https://www.ncbi.nlm.nih.gov/ provide repositories for genomic data, including spatial transcriptomics datasets. The EMBL-EBI Training portal at https://www.ebi.ac.uk/training offers training resources for bioinformatics analysis, including spatial transcriptomics.

FAIR Data Principles

The FAIR Guiding Principles, published in Scientific Data at https://doi.org/10.1038/sdata.2016.18, describe expectations for making data findable, accessible, interoperable, and reusable. Apply these principles when depositing spatial transcriptomics data to maximize scientific impact and reproducibility.

Professional Escalation Criteria

When to Consult a Bioinformatics Specialist

If your analysis requires advanced computational methods such as deconvolution, cell-cell interaction inference, or integration with single-cell RNA-seq data, consult a bioinformatics specialist. The 2022 Briefings in Bioinformatics study and the 2026 Genome Biology benchmarking study demonstrate that tool choice substantially affects results, and specialized expertise improves analysis quality.

When to Consult a Pathologist

For imaging-based platforms, manual phenotyping evaluation by a pathologist can reveal discrepancies with automatic segmentation. The 2025 Nature Communications study performed manual phenotyping evaluation to assess pathologically meaningful comparisons between platforms. If your tissue has complex morphology or your cell types are difficult to distinguish, involve a pathologist in the analysis.

When to Reconsider Platform Choice

If preliminary data show poor gene-histology concordance, low transcript detection, or unexpected expression patterns, reconsider your platform choice. The 2026 Genome Biology study provides a harmonized dataset and technical reference for the spatial transcriptomics community, offering insight into the relative strengths, limitations, and design considerations associated with high-throughput spatial profiling of FFPE tumors. Use this reference to benchmark your data quality.

Applications Across Research Areas

Cancer Research

Spatial transcriptomics has been widely used to profile spatial heterogeneity in multiple cancer types. A 2022 review in Frontiers in Oncology noted that ST has been used to identify and understand special spatial areas such as tumor interface and tertiary lymphoid structures, which exhibit unique tumor microenvironments. The 2025 review in Cancers compared major ST platforms including GeoMx, Visium, and Xenium for lung cancer research, highlighting how ST reveals tumor heterogeneity, immune evasion mechanisms, and spatially distinct cellular subtypes that influence therapy response.

Immunology and Immunotherapy

The 2025 review in Frontiers in Immunology on head and neck squamous cell carcinoma highlighted the importance of ST in uncovering the complexities of the tumor-immune microenvironment and proposed strategies for leveraging these insights to develop more effective immunotherapeutic approaches. The 2025 review in Frontiers in Immunology on single-cell and spatial transcriptomics integration emphasized how these technologies jointly uncover cellular heterogeneity, stromal-immune interactions, and spatial niches driving tumor progression and therapy resistance.

Cardiovascular Research

A review in Europe PMC titled "Decoding cardiac homeostasis and injury: the evolving landscape of spatial transcriptomics" addresses the application of ST to cardiac research. The 2026 review on intracranial aneurysms in Translational Stroke Research discussed how recent advances in spatial transcriptomics enable the study of infiltrating macrophages within the aneurysmal lesion and the identification of pathogenic changes that were previously challenging to probe.

Dermatology

The 2025 review in Current Opinion in Immunology on psoriasis noted that ST and scRNA-seq have led to the identification of distinct cell populations within the skin, associated dysregulated pathways, and critical insight into tissue microenvironments and cell-to-cell interactions.

Veterinary Medicine

A 2025 scoping review in the International Journal of Molecular Sciences examined applications of spatial transcriptomics in veterinary medicine. The review found that commonly used platforms included 10x Visium, Slide-seq, NanoString (GeoMx, CosMx), and MERFISH. Key gaps included limited veterinary representation, interspecies comparisons, standardized methods, public data use, and therapeutic studies.

Frequently Asked Questions

What is the main difference between sequencing-based and imaging-based spatial transcriptomics?

Sequencing-based platforms such as Visium and Slide-seq capture all expressed genes using spatially barcoded capture surfaces and read them out through next-generation sequencing. Imaging-based platforms such as Xenium, CosMx, and MERFISH use fluorescence microscopy to detect a predefined panel of genes at single-cell resolution. Sequencing-based methods support unbiased gene discovery but generally have lower spatial resolution, while imaging-based methods provide higher resolution but require you to select genes in advance.

How do I choose between 10x Visium and 10x Xenium?

Choose Visium if you need whole-transcriptome coverage for unbiased discovery or if you do not have a predefined gene panel. Choose Xenium if you need single-cell resolution and have a defined set of genes relevant to your question. The 2026 Genome Biology study compared Visium and Xenium on matched FFPE tumor sections and found that each platform has distinct strengths in transcript detection, gene-histology concordance, and cell type recovery. Consider your resolution requirements and whether discovery or targeted analysis matters more for your study.

What is the difference between Xenium Multi-Tissue and Xenium Prime panels?

The 2026 Genome Biology study provided the first same-sample comparison of Xenium Multi-Tissue (377 genes) and Xenium Prime (5,000 genes). The study highlighted key differences in transcript recovery and spatial signal despite shared chemistry and imaging infrastructure. The larger panel does not simply provide more genes without tradeoffs, so evaluate detection efficiency and data quality when choosing panel size.

How does off-target probe binding affect Xenium data?

A 2026 study in eLife documented off-target probe binding in Xenium gene panels, identifying at least 14 of 313 genes in a breast cancer panel potentially impacted by off-target binding to protein-coding genes. For some genes, the expression patterns detected by Xenium reflected the aggregate expression of the target and predicted off-target genes instead of the target gene alone. Use the Off-target Probe Tracker tool to screen panels and validate suspicious genes with orthogonal methods.

Can I use FFPE samples with spatial transcriptomics platforms?

Yes, most major platforms support FFPE samples. The 2026 Genome Biology study benchmarked Visium v1, Visium v2/CytAssist, Visium HD, Xenium, and CosMx using matched FFPE human tumor sections from six cancer types. The 2025 Nature Communications study used FFPE tumor samples to compare CosMx, MERFISH, and Xenium. However, tissue age affects data quality, so older FFPE blocks may produce poorer results.

How do I estimate cell-type composition from spot-level spatial transcriptomics data?

Spot-level platforms such as Visium capture RNA from multiple cells per spot, requiring computational deconvolution to estimate cell-type proportions. A 2022 study in Briefings in Bioinformatics compared 10 deconvolution methods and concluded that RCTD and stereoscope achieve more robust and accurate inferences. Choose validated deconvolution tools and validate results with orthogonal methods where possible.

What sequencing platforms are compatible with 10x Visium?

A 2023 study in BMC Genomics compared the Illumina NextSeq 2000 and GeneMind Genolab M sequencing platforms for 10x Genomics Visium spatial transcriptomics. The study found that the GeneMind Genolab M produces highly consistent results with the Illumina NextSeq 2000, with similar performance in sequencing quality and detection of UMI, spatial barcode, and probe sequence. This offers a potential lower-cost sequencing alternative.

What are the main challenges in spatial transcriptomics data analysis?

The 2026 review in Biotechnology Advances noted that spatial transcriptomics faces several challenges, including technical complexity, difficulties in data analysis, and lack of standardization. The 2026 benchmarking study in Genome Biology demonstrated substantial variability in cell-cell interaction inference tool performance across spatial resolutions, tissue contexts, and platforms. Budget time and resources for computational analysis and consider consulting bioinformatics specialists for advanced methods.

Related Bioinformatics Guides

• Modern Transcriptomics: From Bulk RNA-Seq to Single-Cell and Spatial Resolution
• Spatial Transcriptomics: Mapping the Cellular Atlas
• Spatial Transcriptomics Alignment and Cellular Neighborhood Analysis
• ChIP-Seq Bioinformatics Workflows
• Docker and Containerization in Reproducible Research

References and Further Reading

• EMBL-EBI Training. European Bioinformatics Institute.
• NCBI Data Resources. National Center for Biotechnology Information.
• Genomic Data Sharing Policy. National Institutes of Health.
• The FAIR Guiding Principles. Scientific Data.
• Comparison of imaging based single-cell resolution spatial transcriptomics profiling platforms using formalin-fixed paraffin-embedded tumor samples.. Nature communications, 2025.
• Systematic comparison of sequencing-based spatial transcriptomic methods.. Nature methods, 2024.
• A technical comparison of spatial transcriptomics platforms across six cancer types.. Genome biology, 2026.
• Comparison of imaging-based single-cell resolution spatial transcriptomics profiling platforms using formalin-fixed, paraffin-embedded tumor samples.. Research square, 2025.
• Comparison of imaging-based single-cell resolution spatial transcriptomics profiling platforms using formalin-fixed, paraffin-embedded tumor samples.. bioRxiv : the preprint server for biology, 2024.
• Spatial transcriptomics: integrating platforms and computational approaches for clinical insights.. Biotechnology advances, 2026.
• A comprehensive comparison on cell-type composition inference for spatial transcriptomics data.. Briefings in bioinformatics, 2022.
• Comparison of the Illumina NextSeq 2000 and GeneMind Genolab M sequencing platforms for spatial transcriptomics.. BMC genomics, 2023.
• Evidence of off-target probe binding affecting 10x Genomics Xenium gene panels compromise accuracy of spatial transcriptomic profiling.. 2026.
• Decoding cardiac homeostasis and injury: the evolving landscape of spatial transcriptomics
• Cycle-consistent deep generative modeling unifies cellular states across unpaired spatial and single-cell modalities. 2026.
• Characterizing Infiltrating Macrophages in Intracranial Aneurysm with IA Animal Models and Spatial Transcriptomics.. 2026.
• FineST: contrastive learning integrates histology and spatial transcriptomics for nuclei-resolved ligand-receptor analysis.. 2026.
• Benchmarking tools for deciphering cellular crosstalk in spatially-resolved transcriptomics.. 2026.
• Charting spatial ligand-target activity using Renoir.. 2026.
• Spatial transcriptomics technology in cancer research. Frontiers in Oncology, 2022.
• Spatial Transcriptomics in Lung Cancer and Pulmonary Diseases: A Comprehensive Review. Cancers, 2025.
• A review of spatial transcriptomics in psoriasis: new insights into cellular contributions.. Current Opinion in Immunology, 2025.
• Enhancing RNA Capture Efficiency in Spatial Transcriptomics: A Review of Innovative Technologies and Strategies. International Journal of Molecular Sciences, 2025.
• Applications of Spatial Transcriptomics in Veterinary Medicine: A Scoping Review of Research, Diagnostics, and Treatment Strategies. International Journal of Molecular Sciences, 2025.
• Single-cell and spatial transcriptomics integration: new frontiers in tumor microenvironment and cellular communication. Frontiers in Immunology, 2025.
• Mapping immunotherapy potential: spatial transcriptomics in the unraveling of tumor-immune microenvironments in head and neck squamous cell carcinoma. Frontiers in Immunology, 2025.
• Mapping biology in space: from spatial transcriptomics platforms to analytical tools and databases. Science Bulletin, 2026.
• Standardized metrics for assessment and reproducibility of imaging-based spatial transcriptomics datasets. Nature Biotechnology, 2026.

This article is educational and does not replace validated analysis plans, institutional policy, clinical interpretation, or specialist review.